Login

Journal Front Page

News & Events

  • Call for article for January 2025 issue
    • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 December, 2024 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • October 2024 Issue published
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 13, Issue 4 (October 2024 Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
    • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
    • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
    • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

RECENT ADVANCEMENT IN THE TREATMENT OF URTICARIA: REVIEW

Adamu Mustapha, Mohammed Ali Gada, Alhaji Kolo Shettima, Sandip Prasad Tiwari*

Faculty of Pharmacy, Kalinga University, Naya Raipur, Chhattisgarh India (492101)

ABSTRACT

Urticaria commonly known as hives, is a skin allergy condition which is characterized by itching, raised welts or rash. Over the years, research and medical innovation have led to significant Advancements in the treatment of urticaria, offering hope and relief to millions of individuals worldwide. There are many recent advancements in the treatment of different classification of Acute and Chronic urticaria. This abstract provides an overview of recent development or Advancement in urticaria treatment. Firstly, to proceed into the understanding of urticaria’s underlying causes, emphasizing the difference between acute and chronic forms of condition. The most exciting way in recent Advance treatment of urticaria is the Advantage of monoclonal antibodies, such as Omalizumab and Dupilumab which target specific pathways in histamine release and inflammation. These biological drugs have shown remarkable efficacy, particularly in the severe cases of urticaria. Additionally, recent research has unveiled an autoimmune component in chronic urticaria treatment, leading to advancements in immune- modulatory therapies tailored to treat the aspect of the condition. Furthermore, short-term use of systemic corticosteroids has become a viable option for treatment of acute urticaria, minimizing potential long term side effects. In addition, 80% of the cases with no exogenous allergy trigger on underlying systemic disease are identified, and the condition is referred to as chronic idiopathic urticaria. In addition to medical interventions, lifestyle management plays a critical role in urticaria treatment. Patients are advised to identify and avoid triggers, with of the outbreaks. In conclusion, the recent advancements in the treatment of urticaria offer renewed hope and improved outcomes for individuals affected by this condition. The approaches, introduction of biologics and enhanced antihistamines, the landscape of urticaria management indeed, provide patients seeking relief from the challenges of skin disorder.

Keywords: Urticaria, Diagnosis, Treatment, Corticosteroids.


[Full Text Article]